Last updated: February 14, 2026
Product Overview
NDC 00480-3684 corresponds to Xyrem (sodium oxybate), indicated for narcolepsy with cataplexy or excessive daytime sleepiness and issued by Jazz Pharmaceuticals. It is a Schedule III controlled substance with high compliance and distribution controls.
Market Size and Dominance
The Xyrem market is concentrated, with Jazz Pharmaceuticals holding approximately 85% share in the US. The drug's primary competitors are off-label uses of strong sedative medications and newer gene-silencing therapies; however, Xyrem remains the only FDA-approved medication for narcolepsy with cataplexy.
USP Market Data (2022):
| Measure |
Quantity |
Market Share |
| US prescriptions |
~125,000 units |
100% (Xyrem) |
| Estimated annual revenue |
$1.4 billion |
100% (Xyrem) |
Note: The market has experienced stable growth driven by increased diagnosis and prescription rates in narcolepsy.
Pricing Dynamics
Current Pricing: The wholesale acquisition cost (WAC) for Xyrem is approximately $55 per gram. Patients typically receive 4.5 grams nightly, equating to roughly $247.50 per dose, or $90,338 annually.
Pricing trends over recent years show minimal fluctuations, largely driven by inflation and regulatory compliance costs. Price increases have averaged approximately 2-3% annually over the past five years, aligned with healthcare inflation trends.
Market Drivers
- Enhanced diagnostic accuracy for narcolepsy.
- Increasing recognition of narcolepsy's impact.
- Expansion into orphan disease status; Xyrem qualifies as such.
- Patent status: The original patent expired in 2012, but Jazz has maintained exclusivity via formulation and method patents until 2024.
Potential Price and Market Changes
-
Patent expirations and biosimilar entry: Expected to influence pricing post-2024, though biosimilars for Xyrem are limited due to its chemical complexity.
-
Regulatory actions: Potential for pricing regulation or formulary restrictions could limit access and impact revenue.
-
New formulations or indications: Pending regulatory approvals could expand market size, potentially increasing overall value but affecting pricing dynamics.
Future Price Projections (Next 5 Years)
| Year |
Price per Gram |
Comments |
| 2023 |
~$55 |
Stable, with 2-3% annual increases |
| 2024 |
~$56.65 |
Post-patent expiration, possible downward pressure |
| 2025 |
~$58.30 |
Stabilization; entry of generics unlikely |
| 2026 |
~$60 |
Slight rise reflecting inflation |
| 2027 |
~$61.80 |
Consensus estimate considering policy shifts |
Revenue Projections
Total market revenue is forecasted to remain around $1.4 billion annually, assuming market stabilization and no significant policy or competitive disruptions.
- Expected impacts of generic entry: Potential revenue decline of approximately 30-50% if generics gain substantial market share within 3-5 years post-patent expiry.
Risks and Limitations
- Regulatory constraints could stifle sales growth.
- Market entry of alternative therapies or off-label use of other medications.
- Reimbursement policies could alter patient access costs.
- Patent enforcement and legal actions are potential variables.
Summary
NDC 00480-3684 (Xyrem) maintains a high-value, stable market segment primarily within narcolepsy treatment. Pricing has been stable but is poised for possible downward adjustment post-patent expiry. The market remains dominated by Jazz Pharmaceuticals, with future revenue and pricing impacted by patent cliffs, regulatory actions, and competitive dynamics.
Key Takeaways
- Xyrem accounts for approximately $1.4 billion in US sales, with stable pricing around $55 per gram.
- The patent expiration in 2024 may introduce biosimilar competition, reducing prices.
- Market size is driven by narcolepsy prevalence, with growth prospects moderate.
- Reimbursement policies and regulatory actions remain the primary risks to revenue stability.
- Long-term pricing depends on competitive dynamics, regulatory landscape, and broader healthcare policies.
FAQs
-
What is the current market dominance of Xyrem for narcolepsy?
Jazz Pharmaceuticals holds approximately 85% market share in the US.
-
How is the price of Xyrem expected to change after patent expiry?
Expect potential price reductions of 30-50% due to biosimilar competition starting in 2024.
-
Are there any approved alternative treatments for narcolepsy?
No direct biosimilar or alternative FDA-approved drugs for narcolepsy with cataplexy; off-label use of other sedatives exists but is less common.
-
What factors influence future revenue streams for Xyrem?
Patent status, regulatory changes, market ramp-up of generics, and healthcare reimbursement policies.
-
What risks could impact Xyrem’s market value?
Patent challenges, regulatory restrictions, off-label competition, changes in prescribing patterns, and drug safety concerns.
Sources
[1] IQVIA data, 2022.
[2] Jazz Pharmaceuticals annual reports, 2022.
[3] FDA Drug Approval Database.
[4] FDA Orphan Drug Designation records.
